SMARCA4 and non-small cell lung carcinoma: Our findings show that the synthetic lethal interaction between SMARCA4 loss and CDK4/6 inhibition, mediated by cyclin D1 deficiency, is a common druggable vulnerability of NSCLC and SCCOHT, despite their differences in tissue of origin and mutation landscape.